Ambulatory blood pressure as a predictor of cardiovascular risk: What’s new?

Slides:



Advertisements
Similar presentations
Valsartan Antihypertensive Long-Term Use Evaluation Results
Advertisements

Resistant hypertension increases patients’ cardiovascular risk 30% of all treated patients develop resistant hypertension [1-5]. Resistant hypertension.
Can we prevent stent restenosis after coronary stent implantation
Overcoming the challenge of blood pressure control in prediabetic and diabetic patients: PICASSO T2D Study Efficacy and tolerability of fixed dose combination.
Cholesterol quintile (mg/dL)
Clinical Trial Results. org Pexelizumab for Acute ST-Elevation Myocardial Infarction in Patients Undergoing Primary Percutaneous Coronary Intervention.
Maximum home blood pressure: a novel indicator of target-organ damage in hypertension  Blood pressure variability has recently been shown to be a strong.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
William B. Kannel, MD, FACC Former Director, Framingham Heart Study
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.
Systolic hypertension not an isolated problem Michael Weber, MD Professor of Medicine Associate Dean Downstate College of Medicine State University of.
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
Can pharmacists improve outcomes in hypertensive patients? Sookaneknun P (1), Richards RME (2), Sanguansermsri J(1), Teerasut C (3) : (1)Faculty of Pharmacy,
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
To assess the prognostic value of variability in home-measured blood pressure (BP) and heart rate (HR) in a general population. Objective: Methods: BP.
Central blood pressure: what do we really know today?
Slide 1 Downloaded from Population Impact of Losartan Use on Stroke in the European Union (EU)
Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13): ?
Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Long-term Risk of Mortality and End-Stage Renal Disease.
Long-term prognostic value of white coat hypertension: an insight from diagnostic use of both ambulatory and home blood pressure measurements Reference:
Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Safety and Efficacy of Low Blood Pressures Among.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Journal Club February 7, 2014 Sadie T. Velásquez, MD.
Date of download: 6/22/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Hypertension J Am Coll Cardiol. 2006;48(8):
Over Time Additional Risk Factors Can Progress: Effect of Cholesterol and BP on CHD Risk in MRFIT Trial
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Making Sense of Statistics in Clinical Trial Reports:
Date of download: 9/19/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association Between Endoscopic vs Open Vein-Graft.
Summary of “A randomized trial of standard versus intensive blood-pressure control” The SPRINT Research Group, NEJM, DOI: /NEJMoa Downloaded.
Antonio Coca, MD, PhD, FRCP, FESC
Dr John Cox Diabetes in Primary Care Conference Cork
An analysis of 22,672 patients from the CLARIFY registry
The SPRINT Research Group
Blood Pressure and Age in Controlling Hypertension
Copyright © 2011 American Medical Association. All rights reserved.
Successful CTO PCI Associated with Lower Mortality Risk
Pulmonary hypertension adversely affects short- and long-term survival after mitral valve operation for mitral regurgitation: Implications for timing.
Copyright © 2007 American Medical Association. All rights reserved.
United States Preventive Services Task Force: Recommendations for ABPM
51st Annual Scientific Session for the LIFE Investigators
Systolic Blood Pressure Intervention Trial (SPRINT)
Progress and Promise in RAAS Blockade
Cyrus J. Parsa, MD, Linda K. Shaw, MS, J. Scott Rankin, MD, Mani A
Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
VALUE Trial design: Hypertensive patients at high cardiovascular risk were randomized to valsartan (n = 7,649) vs. amlodipine (n = 7,596). Results (p =
Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);
Figure 1 Diagram showing analysis flow of patient selection and treatment allocation of ONTARGET/TRANSCEND. Figure 1 Diagram showing analysis flow of patient.
Kaplan-Meier curves: revascularisation rate (PCI or CABG) was significantly higher (p
A decade after the Surgical Treatment for Ischemic Heart Failure (STICH) trial: Weaving firm clinical recommendations from lessons learned  Robert E.
Kaplan-Meier estimate of mortality in 1798 propensity score matched pairs with a propensity score >0.5 for the whole observational period. Kaplan-Meier.
(A) Meta-analysis of repeat revascularisation in randomised trials.
DENERHTN Trial design: Patients with resistant hypertension were randomized to renal denervation plus standardized stepped-care antihypertensive treatment.
Characteristics of included studies
(A) Multivariable Cox regressions showing the association of higher CHA2DS2-Vasc scores (≥6) and (B) R2CHA2DS2-Vasc scores (≥7) with 1-year mortality (CABG,
Cox regression of proportion mortality in the first 8 years for patients with three-vessel disease with a significant difference between the treatment.
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
Glenn N. Levine et al. JACC 2011;58:e44-e122
Kaplan–Meyer survival curve of 1313 patients following primary PCI
ASCOT: randomised trial showing a decrease in cardiovascular mortality in patients treated with amlodipine/perindopril compared with atenolol/thiazide.
EMPA-REG OUTCOME: Cumulative incidence of the primary outcome
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
Genetic predisposition to CHD modifies the increased CHD risk associated with smoking (*) ORs adjusted for age, gender, total energy intake, alcohol intake,
A model of variation and accelerating factors in the process of acute care chain of patients with STEMI going for primary PCI. PCI, percutaneous coronary.
Effect of PCI on 3 to 5-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval.
Result of coronary angiogram among patients with and without diabetes admitted with first-time acute coronary syndrome (a significant stenosis was defined.
End point Valsartan Valsartan+HCTZ p
Kaplan-Meier estimate of mortality in the two treatment strategies with significant difference between the two groups (log-rank test
P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.
Relationship between 6-month all-cause mortality and the three types of heart failure adjusted for age ≥75 years, peripheral edema at admission, systolic.
Average change in blood pressure (BP) from recruitment to 6-month postrecruitment in intervention and control patients >50 years included due to having.
Presentation transcript:

Ambulatory blood pressure as a predictor of cardiovascular risk: What’s new?

Office, home, and ambulatory blood pressures as predictors of cardiovascular risk Niiranen TJ et al. Hypertension. 2014;64: Many cross-sectional and follow-up studies have shown that home and ambulatory blood pressure measurements are more strongly associated with hypertensive target-organ damage and cardiovascular prognosis than office blood pressure. However, data comparing home versus ambulatory blood pressure in a prognostic setting are extremely scarce because only 2 studies with contradictory results and inadequate end points have been published. The main purpose of this study is to elucidate the prognostic significance of office versus home versus ambulatory blood pressure. The study included 502 patients from Finland with a follow-up of 16.1±3.9 years. The primary end point was the combination of cardiovascular mortality, nonfatal myocardial infarction, nonfatal stroke, hospitalization for heart failure, percutaneous coronary intervention, and coronary artery bypass graft surgery. Only the first event was included in the analysis.

Ambulatory blood pressure (BP), especially nighttime BP, is prognostically superior to office and home BP Office, home, and ambulatory blood pressures as predictors of 16.1-year risk of cardiovascular events. The figure is adjusted for other cardiovascular risk factors. Niiranen TJ et al. Hypertension. 2014;64:

Effective decrease in nocturnal systolic blood pressure with amlodipine/perindopril Dolan E et al; ASCOT Investigators. J Hypertens. 2009;27: Better survival among patients treated with amlodipine/perindopril related to better nighttime blood pressure control 12345(years) Nighttime SBP Mean difference = –2.2 mm Hg Atenolol/thiazide Amlodipine/Perindopril